OUTREACH CORE ABSTRACT The overarching goal of the Outreach Core is to improve the prevention, detection, treatment and survival from cancer by integrating community engagement practices with cancer research strategies. During the past five years, the Cancer Outreach Core has been an integral part of the CDU-UCLA Cancer Center Partnership. We have strengthened relationships with predominantly African American community members and organizations; identified cancer-related priorities in this community; organized four large community cancer conferences; supported three seed grants that were conducted in South Los Angeles, each with an academic and a community investigator; developed publications in peer-reviewed journals, each with community authors; and obtained new grant support, including funding for the first Patient Navigation Program and Wellness Center for South Los Angeles. In short, we have successfully engaged the community in South Los Angeles in research to reduce cancer disparities. We have also contributed to the training of minority junior faculty, community faculty and students, which is an important goal of the CDU-UCLA Cancer Center Partnership. Based on our experience in the current funding cycle and the advice of the Program Steering Committee, we will maintain the strong features of the Cancer Outreach Core and add new components that build on the work we have accomplished to date and the expertise of our diverse team of community and academic faculty from UCLA and CDU. The partnership will benefit CDU by building a strong foundation for community- partnered cancer disparities research; and will benefit UCLA by broadening outreach opportunities to South Los Angeles.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54CA143931-06
Application #
9037348
Study Section
Special Emphasis Panel (ZCA1-PCRB-C (O1))
Project Start
2009-09-29
Project End
2020-08-31
Budget Start
2015-09-25
Budget End
2016-08-31
Support Year
6
Fiscal Year
2015
Total Cost
$268,250
Indirect Cost
$81,316
Name
Charles R. Drew University of Medicine & Science
Department
Type
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Boonyaratanakornkit, Viroj; Hamilton, Nalo; Márquez-Garbán, Diana C et al. (2018) Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer. Mol Cell Endocrinol 466:51-72
Chung, Seyung S; Dutta, Pranabananda; Austin, David et al. (2018) Combination of resveratrol and 5-flurouracil enhanced anti-telomerase activity and apoptosis by inhibiting STAT3 and Akt signaling pathways in human colorectal cancer cells. Oncotarget 9:32943-32957
Maxwell, Annette E; Young, Sandra; Moe, Emily et al. (2018) Understanding Factors that Influence Health Care Utilization Among Mixtec and Zapotec Women in a Farmworker Community in California. J Community Health 43:356-365
Maxwell, Annette E; Castillo, Laura; Arce, Anthony A et al. (2018) Eating Veggies Is Fun! An Implementation Pilot Study in Partnership With a YMCA in South Los Angeles. Prev Chronic Dis 15:E132
Elshimali, Yahya I; Wu, Yong; Khaddour, Hussein et al. (2018) Optimization Of Cancer Treatment Through Overcoming Drug Resistance. J Cancer Res Oncobiol 1:
Hamilton, Nalo; Austin, David; Márquez-Garbán, Diana et al. (2017) Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci 18:
La, V; Fujikawa, R; Janzen, D M et al. (2017) Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. NPJ Precis Oncol 1:
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:
Wu, Yong; Yu, Xiaoting; Yi, Xianghua et al. (2017) Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res 77:1383-1394
Wang, Piwen; Solorzano, Walter; Diaz, Tanya et al. (2017) Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp 13:1-11

Showing the most recent 10 out of 90 publications